Trial Profile
AN OPEN LABEL DOSE RANGING, EFFICACY, SAFETY AND TOLERABILITY PHASE IIA STUDY OF TOPICAL RECOMBINANT LYSOSTAPHIN GEL FORMULATION IN SUBJECTS WITH UNCOMPLICATED STAPHYLOCOCCUS AUREUS SKIN AND SKIN STRUCTURE INFECTIONS.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Lysostaphin (Primary)
- Indications Staphylococcal infections
- Focus Therapeutic Use
- 21 Jan 2012 New trial record